Michael focuses on corporate and securities law and possesses more than 30 years of experience providing general corporate representation to public and private biopharmaceutical, medical device, diagnostic, instrumentation, and life sciences companies.
Michael applies his broad experience in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions to each engagement. He has undertaken over 300 venture capital financings raising an estimated $7 billion for his clients, recently assisting Auris Health to raise over $650 million in financings before its sale to J&J for up to $5.75 billion.
He also brings extensive experience negotiating strategic alliances, representing clients in significant collaborations with GSK, Amgen, Schering-Plough, J&J, Daiichi, Astellas, King Pharmaceuticals, and most recently Pfizer, Merck, Baxter, Eisai, and Dainippon Sumitomo Pharma Co., Ltd.
Michael was the lead lawyer on the initial public offerings for Illumina, Neurocrine Biosciences, Cytokinetics, Pain Therapeutics, NeurogesX, Sequana Therapeutics, Ciphergen Biosystems, Argonaut Technologies, and Microcide Pharmaceuticals.
Michael was also the lead lawyer responsible for negotiating many notable biopharmaceutical spin-outs, including Onyx Pharmaceuticals (Chiron-Cetus), Tularik (Genentech), X-Ceptor (Ligand Pharmaceuticals), Metabasis (Gensia Sicor), and as well on the reverse merger of Transcept Pharmaceuticals with Novacea, creating a new publicly traded entity.